StockMacro
Menu

Serina Therapeutics

$1.12 -42% in 6 monthsMarket cap $29.8M

SER on XASE, Health Care, Serina Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 70% in 12 months while free cash outflow reached $22.8M against $19.4M cash.

  • BadA share registration was filed in the last 90 days
  • WatchSimilar filers trailed sector by a median 23.8 points in six months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Industry
Pharmaceutical preparations (Health Care)
Employees
16
Website
serinatherapeutics.com
Listed
NYSE American, US
Last results
12 Nov 2026
Next results
expected around 24 Mar 2027 (an estimate: a year ago it reported on 25 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $125K, net loss $7.9M.
Quarter to 31 Dec 2021: revenue –, net income -$2.2MQuarter to 31 Mar 2022: revenue $5K, net income -$2.7MQuarter to 31 Mar 2022: revenue $5K, net income -$2.7MQuarter to 30 Jun 2022: revenue $12K, net income -$2.6MQuarter to 30 Jun 2022: revenue $12K, net income -$2.6MQuarter to 30 Sep 2022: revenue $9K, net income -$2.4MQuarter to 30 Sep 2022: revenue $9K, net income -$2.4MQuarter to 31 Dec 2022: revenue $8K, net income -$2.7MQuarter to 31 Dec 2022: revenue $8K, net income -$2.7MQuarter to 31 Mar 2023: revenue $10K, net income -$3.3MQuarter to 31 Mar 2023: revenue $10K, net income -$3.3MQuarter to 30 Jun 2023: revenue $9K, net income -$2.7MQuarter to 30 Jun 2023: revenue $9K, net income -$2.7MQuarter to 30 Sep 2023: revenue $67K, net income -$5.4MQuarter to 30 Sep 2023: revenue $67K, net income -$5.4MQuarter to 31 Dec 2023: revenue –, net income -$3.5MQuarter to 31 Mar 2024: revenue $5K, net income -$9.4MQuarter to 31 Mar 2024: revenue $5K, net income -$9.4MQuarter to 30 Jun 2024: revenue $51K, net income $5.2MQuarter to 30 Jun 2024: revenue $51K, net income $5.2MQuarter to 30 Sep 2024: revenue $14K, net income $1.4MQuarter to 30 Sep 2024: revenue $14K, net income $1.4MQuarter to 31 Mar 2025: revenue $0, net income -$4.8MQuarter to 31 Mar 2025: revenue $0, net income -$4.8MQuarter to 30 Jun 2025: revenue $130K, net income -$6.4MQuarter to 30 Jun 2025: revenue $130K, net income -$6.4MQuarter to 30 Sep 2025: revenue $0, net income -$4.6MQuarter to 30 Sep 2025: revenue $0, net income -$4.6MQuarter to 31 Dec 2025: revenue $0, net income -$3.3MQuarter to 31 Dec 2025: revenue $0, net income -$3.3MQuarter to 31 Mar 2026: revenue –, net income -$6.9MQuarter to 30 Jun 2026: revenue $0, net income -$6.4MQuarter to 30 Jun 2026: revenue $0, net income -$6.4MQuarter to 30 Sep 2026: revenue $125K, net income -$7.9MQuarter to 30 Sep 2026: revenue $125K, net income -$7.9M
31 Dec 2021RevenueNet incomeNet losstallest bar $9.4M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$125K-$7.9M
30 Jun 2026$0-$6.4M
31 Mar 2026–-$6.9M
31 Dec 2025$0-$3.3M
30 Sep 2025$0-$4.6M
30 Jun 2025$130K-$6.4M
31 Mar 2025$0-$4.8M
30 Sep 2024$14K$1.4M
30 Jun 2024$51K$5.2M
31 Mar 2024$5K-$9.4M
31 Dec 2023–-$3.5M
30 Sep 2023$67K-$5.4M
30 Jun 2023$9K-$2.7M
31 Mar 2023$10K-$3.3M
31 Dec 2022$8K-$2.7M
30 Sep 2022$9K-$2.4M
30 Jun 2022$12K-$2.6M
31 Mar 2022$5K-$2.7M
31 Dec 2021–-$2.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – $116K
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$24.5M -$18.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -312% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$22.8M –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $19.4M $8.6M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $3.2M $2.9M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$16.2M (net cash) -$5.7M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.23 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $0.52
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 2.1 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Serina TherapeuticsSER (this company) $29.8Mloss–––
NextCureNXTC $29.5Mloss–––
NanoViricidesNNVC $29.1Mloss–––
Rein TherapeuticsRNTX $29.1Mloss–––
AYTU BioPharmaAYTU $28.9Mloss0.49-8.1%-34.3%
ProMIS NeurosciencesPMN $28.4Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-3.6%

27 13F filers vs 28

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

9.3%

2.5M shares held by 13F filers (30 Sep 2026) of 26.6M outstanding (10 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

0.2%

47K shares sold short (30 Oct 2026) of 26.6M outstanding (10 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

1.0

47K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+6.7%

44K shares sold short in the report before, 47K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

48%

48% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 39%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

1

1 article in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

1 article in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $1.12 on 20 Nov 2026, -70% over 12 months (12-month range $1.12 to $4.26)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $232K in the last 12 months (the 12 months before: -$792K).
Revenue per quarter. Revenue $125K in the latest quarter.
Capital spending per quarter. Capital spending $3K in the latest quarter, -77% on a year earlier.
Institutional holders (13F filers). 27 13F filers reported holding it in the latest 13F quarter, +17% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
24 Aug 20268-K and other filingsRegistered new securities for sale (S-1)
23 Jul 20268-K and other filingsDirector or officer change
22 Jul 20268-K and other filingsDirector or officer change
22 Jul 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Apr 20268-K and other filingsDirector or officer change
23 Mar 20268-K and other filingsDirector or officer change
23 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Feb 2026Sharp changeShort interest spike: short interest spike, 1.0M vs usual 35K (2026-01-30); 34.2x the same period a year earlier
15 Jan 20268-K and other filingsDelisting notice or listing transfer
22 May 20258-K and other filingsDirector or officer change
22 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Feb 20258-K and other filingsDirector or officer change
14 Jan 20258-K and other filingsDirector or officer change
24 Dec 20248-K and other filingsCompleted an acquisition or asset sale
18 Dec 20248-K and other filingsDirector or officer change
18 Dec 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Sep 20248-K and other filingsDirector or officer change
15 Aug 20248-K and other filingsDirector or officer change
18 Jul 20248-K and other filingsDirector or officer change
12 Jul 20248-K and other filingsDirector or officer change
3 Jul 20248-K and other filingsRegistered new securities for sale (S-1)
15 Jun 20248-K and other filingsRegistered new securities for sale (S-1)
3 May 20248-K and other filingsRegistered new securities for sale (S-1)
3 May 20248-K and other filingsChanged its auditor
17 Apr 20248-K and other filingsDirector or officer change
1 Apr 20248-K and other filingsDirector or officer change
1 Apr 20248-K and other filingsCompleted an acquisition or asset sale
11 Jan 20248-K and other filingsDirector or officer change
1 Dec 20238-K and other filingsDirector or officer change
1 Dec 20238-K and other filingsA major agreement ended
8 Sep 20238-K and other filingsDirector or officer change
8 Sep 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
24 Jul 20238-K and other filingsDelisting notice or listing transfer
23 May 20238-K and other filingsDelisting notice or listing transfer
26 Apr 20238-K and other filingsDelisting notice or listing transfer
15 Mar 20238-K and other filingsDirector or officer change
15 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Dec 20228-K and other filingsDirector or officer change
12 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
25 Nov 20228-K and other filingsDelisting notice or listing transfer
3 Mar 20228-K and other filingsDirector or officer change
30 Dec 20218-K and other filingsDirector or officer change
30 Dec 2021Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
23 Nov 20218-K and other filingsDelisting notice or listing transfer
Insider net buying (open market)
Month from 1 May 2024: $252K published
Month from 1 Jun 2024: $131K published
Month from 1 Aug 2024: $259K published
Month from 1 Sep 2024: $134K published
Month from 1 Dec 2024: $18K published
Month from 1 Jul 2025: -$207K published
Month from 1 Aug 2025: -$411K published
Month from 1 Oct 2025: -$87K published
Month from 1 Nov 2025: -$104K published
Month from 1 Dec 2025: -$80K published
Month from 1 Jan 2026: -$94K published
Month from 1 Feb 2026: -$20K published
Month from 1 Mar 2026: -$116K published
Month from 1 May 2026: $57K published
Month from 1 Jun 2026: $19K published
Month from 1 Jul 2026: $2K published
Revenue per quarter
Quarter ended 31 Mar 2022: $5K, -91% on a year earlier; public on 14 May 2022
Quarter ended 30 Jun 2022: $12K, -68% on a year earlier; public on 13 Aug 2022
Quarter ended 30 Sep 2022: $9K, -62% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $8K; public on 1 Apr 2023
Quarter ended 31 Mar 2023: $10K, +100% on a year earlier; public on 13 May 2023
Quarter ended 30 Jun 2023: $9K, -25% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $67K, +644% on a year earlier; public on 15 Nov 2023
Quarter ended 31 Mar 2024: $5K, -50% on a year earlier; public on 15 May 2024
Quarter ended 30 Jun 2024: $51K, +467% on a year earlier; public on 10 Aug 2024
Quarter ended 30 Sep 2024: $14K, -79% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $130K, +155% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $0, -100% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 26 Mar 2026
Quarter ended 30 Jun 2026: $0, -100% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $125K; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 30 Sep 2023: $119K; public on 13 Nov 2024
Quarter ended 31 Mar 2024: $14K; public on 15 May 2024
Quarter ended 30 Sep 2024: $3K, -97% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $46K; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $13K, +333% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Mar 2026: $25K; public on 15 May 2026
Quarter ended 30 Jun 2026: $28K, -39% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $3K, -77% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Mar 2024 report: 13; public on 15 May 2024
30 Jun 2024 report: 21; public on 14 Aug 2024
30 Sep 2024 report: 24; public on 14 Nov 2024
31 Dec 2024 report: 24; public on 14 Feb 2025
31 Mar 2025 report: 25; public on 15 May 2025
30 Jun 2025 report: 21; public on 14 Aug 2025
30 Sep 2025 report: 23; public on 14 Nov 2025
31 Dec 2025 report: 22; public on 17 Feb 2026
31 Mar 2026 report: 24; public on 15 May 2026
30 Jun 2026 report: 28; public on 14 Aug 2026
30 Sep 2026 report: 27; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $0 published
Month from 1 Sep 2022: $0 published
Month from 1 Sep 2023: $341K published
Month from 1 Jun 2025: $0 published
Month from 1 Sep 2025: -$18K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $2K (9 Jul 2026), higher than 70% of its own history.
  • Insider net buying (open market): Insiders sold a net $232K in the last 12 months (the 12 months before: -$792K).
  • Revenue per quarter: Revenue $125K in the latest quarter.
  • Capital spending per quarter: Capital spending $3K in the latest quarter, -77% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 57 insider trades

No trades in the last 90 days; the latest was filed 9 Jul 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
9 Jul 2026Stephen K. BrannanDirectorBuy1,000$2.03$2KForm 4
22 Jun 2026Jay VenkatesanDirectorBuy589$1.78$1KForm 4
15 Jun 2026Karen J WilsonDirectorBuy10,100$1.76$18KForm 4
26 May 2026Karen J WilsonDirectorBuy20,000$1.85$37KForm 4
22 May 2026Richard Peter MarshallDirectorBuy12,183$1.65$20KForm 4
24 Mar 2026Randall MoreadithChief Scientific OfficerSellplanned in advance (10b5-1); after exercising options6,500$2.86$19KForm 4
20 Mar 2026Randall MoreadithChief Scientific OfficerSellplanned in advance (10b5-1); after exercising options39,000$2.50$98KForm 4
3 Feb 2026Randall MoreadithChief Scientific OfficerSellplanned in advance (10b5-1); after exercising options6,500$3.03$20KForm 4

27 institutions reported shares at the end of Q3 2026, 9% of the shares outstanding; 3 opened a position, 4 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Sio Capital Management, LLC2.0M7.53%$4.0M+1.0M+100%
Vanguard Capital Management LLC185K0.70%$369K+23K+14%
Ashton Thomas Private Wealth, LLC89K0.33%$178KNew+89K
Waverly Advisors, LLC67K0.25%$135KNo change
Geode Capital Management, LLC32K0.12%$64K-19K-37%
Virtu Financial LLC23K0.09%New+23K
Northern Trust Corp21K0.08%$42KNo change
Vanguard Fiduciary Trust Co20K0.08%$40KNo change
Avidian Wealth Enterprises, LLC19K0.07%$38KNo change
State Street Corp13K0.05%$26KNo change

Federal contracts

All 1 federal contracts

No new award in 12 months; the latest was signed 18 Sep 2019. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
18 Sep 2019Department of Health and Human ServicesNational Institutes of Health$1.7MA SINGLE DOSE LONG-ACTING NON-ADDICTIVE POLYMER CONJUGATE FORMULATION OF BUPRENORPHINE THAT PROVIDES IMMEDIATE AND PROLONGED ANALGESIA FOR POST-OPERATIVE PAINGrantUSAspending

Company events

All 71 company events

In 12 months: 4 director or officer changes, 2 major agreements, 1 delisting notice, 1 share registration. Results releases and routine reports are left out.

FiledWhat happenedSource
26 Aug 2026Signed a major agreementSame filing: sold shares privately8-K
24 Aug 2026Registered new securities for sale (S-1)S-1
23 Jul 2026Director or officer change8-K
22 Jul 2026Director or officer change8-K
21 Apr 2026Director or officer changeSame filing: changed its bylaws or fiscal year8-K
23 Mar 2026Director or officer change; Signed a major agreementSame filing: sold shares privately, changed its bylaws or fiscal year8-K
15 Jan 2026Delisting notice or listing transfer8-K
15 Sep 2025Signed a major agreementSame filing: took on new debt, sold shares privately8-K

Reported lobbying spend: $10K in Q3 2018, $10K in Q2 2018. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Sep 2020EndedBradley Arant Boult Cummings LLPfor Serina Therapeutics, Inc.Not statedFiling
12 Oct 2017NewBradley Arant Boult Cummings LLPfor Serina Therapeutics, Inc.Healthcare issuesHealth issuesFiling

The 5 newest of 31 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 24 Aug 2026Filings record

    Registered new securities for sale (S-1)

  2. 23 Jul 2026Filings record

    Director or officer change

  3. 22 Jul 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 22 Jul 2026Filings record

    Director or officer change

  5. 10 Jul 2026Insiders record

    Brannan Stephen K. (director) bought 1,000 shares of SER ($2,030) (dated 9 Jul 2026)

  6. 23 Jun 2026Insiders record

    Venkatesan Jay (director) bought 589 shares of SER ($1,048) (dated 22 Jun 2026)

  7. 16 Jun 2026Insiders record

    WILSON KAREN J (director) bought 10,100 shares of SER ($17,775) (dated 15 Jun 2026)

  8. 27 May 2026Insiders record

    WILSON KAREN J (director) bought 20,000 shares of SER ($37,000) (dated 26 May 2026)

  9. 23 May 2026Insiders record

    Marshall Richard Peter (director) bought 12,183 shares of SER ($20,102) (dated 22 May 2026)

  10. 21 Apr 2026Filings record

    Director or officer change

  11. 23 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 23 Mar 2026Filings record

    Director or officer change

  13. 11 Feb 2026Short interest and volume change

    had 1.0M shares sold short in the 30 Jan 2026 report, 34× the same report last year.

    Same report last year: 29K; its normal report is 35K.

    See the evidence
    This period
    1.0M (the 30 Jan 2026 report)
    Normal report (median of 24 earlier)
    35K
    Typical spread (median absolute deviation)
    6,842
    How far from its usual level
    +19.4
    Same report last year
    29K
    History used
    673 days
    2025-01-31: 29K2025-02-14: 34K2025-02-28: 31K2025-03-14: 31K2025-03-31: 30K2025-04-15: 25K2025-04-30: 25K2025-05-15: 29K2025-05-30: 29K2025-06-13: 29K2025-06-30: 32K2025-07-15: 39K2025-07-31: 51K2025-08-15: 38K2025-08-29: 215K2025-09-15: 82K2025-09-30: 59K2025-10-15: 69K2025-10-31: 53K2025-11-14: 63K2025-11-28: 43K2025-12-15: 36K2025-12-31: 26K2026-01-15: 85K2026-01-30: 1.0M
    the 30 Jan 2026 report24 earlier reportsnormal: 35K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 15 Jan 2026Filings record

    Delisting notice or listing transfer

  15. 22 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 22 May 2025Filings record

    Director or officer change

  17. 12 Feb 2025Filings record

    Director or officer change

  18. 14 Jan 2025Filings record

    Director or officer change

  19. 24 Dec 2024Filings record

    Completed an acquisition or asset sale (dated 23 Dec 2024)

  20. 20 Dec 2024Insiders record

    Bailey Gregory (director) bought 3,866 shares of SER ($17,745) (dated 19 Dec 2024)

  21. 18 Dec 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 18 Dec 2024Filings record

    Director or officer change

  23. 25 Sep 2024Insiders record

    Bailey Gregory (director) bought 1,137 shares of SER ($6,856) (dated 24 Sep 2024)

  24. 21 Sep 2024Insiders record

    Bailey Gregory (director) bought 14,388 shares of SER ($88,236) (dated 20 Sep 2024)

  25. 17 Sep 2024Insiders record

    MINTZ STEVEN (director) bought 6,000 shares of SER ($38,820) (dated 16 Sep 2024)

  26. 12 Sep 2024Filings record

    Director or officer change

  27. 23 Aug 2024Insiders record

    Bailey Gregory (director) bought 1,776 shares of SER ($14,652) (dated 22 Aug 2024)

  28. 21 Aug 2024Insiders record

    Bailey Gregory (director) bought 19,200 shares of SER ($140,096) (dated 20 Aug 2024)

  29. 20 Aug 2024Insiders record

    MINTZ STEVEN (director) bought 8,943 shares of SER ($58,934) (dated 19 Aug 2024)

  30. 17 Aug 2024Insiders record

    Bailey Gregory (director) bought 6,400 shares of SER ($45,248) (dated 16 Aug 2024)

  31. 15 Aug 2024Filings record

    Director or officer change

  32. 18 Jul 2024Filings record

    Director or officer change

  33. 12 Jul 2024Filings record

    Director or officer change

  34. 3 Jul 2024Filings record

    Registered new securities for sale (S-1)

  35. 28 Jun 2024Insiders record

    MINTZ STEVEN (director) bought 7,600 shares of SER ($70,900) (dated 27 Jun 2024)

  36. 15 Jun 2024Filings record

    Registered new securities for sale (S-1) (dated 14 Jun 2024)

  37. 1 Jun 2024Insiders record

    Bailey Gregory (director) bought 6,378 shares of SER ($60,591) (dated 31 May 2024)

  38. 30 May 2024Insiders record

    Bailey Gregory (director) bought 9,019 shares of SER ($85,680) (dated 29 May 2024)

  39. 25 May 2024Insiders record

    Bailey Gregory (director) bought 3,287 shares of SER ($31,226) (dated 24 May 2024)

  40. 24 May 2024Insiders record

    Bailey Gregory (director) bought 1,422 shares of SER ($13,509) (dated 23 May 2024)

Showing the newest 40 of 88 entries; narrow the window or the kind of data to see older ones.

Not listed: 142 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001708599
Ticker
SER
Domain
serinatherapeutics.com
Hq location
AL|HUNTSVILLE|35806 (1 unverified)
Lobbying client
serina therapeutics
Name
AgeX Therapeutics, Inc., Serina Therapeutics (AL), Inc, Serina Therapeutics Australia Pty Ltd, Serina Therapeutics, Inc.
Uei
EJRNPKNUBNM8, UN1VX3VLFBN6
  • Federal lobbying disclosures (LDA)2 records, 28 data points12 Oct 2017 to 30 Sep 2020
  • SEC Form 13F institutional holdings99 data points31 Mar 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)157 records10 Jul 2017 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)529 data points31 Dec 2016 to 10 Nov 2026
  • SEC Form 4 insider transactions57 records, 224 data points12 Dec 2018 to 9 Jul 2026
  • FINRA short interest (twice monthly)189 data points28 Mar 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1334 data points27 Mar 2024 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 54 data points20 Sep 2018 to 26 Aug 2025